Organization: Adherex Technologies Inc

Adherex to collaborate with AstraZeneca

Adherex Technologies Inc, Ottawa, has entered a collaboration and option agreement with AstraZeneca plc to further develop the company’s cancer compounds including its lead compound, Exherin, as they move toward human trials. The collaboration begins with a preliminary six-month period during which AstraZeneca scientists will work with Adherex compounds. The collaboration may be extended but…

Adherex ends R&D collaboration with Shire

Ottawa’s Adherex Technologies Inc has ended its co-development arrangement with Shire Pharmaceuticals by mutual agreement. The biotechnology firm specializing in cell adhesion technologies is now in discussions with another major pharamceutical partner to develop its Exherin cancer compound, with the stipulation that such a collaboration that does not require matching R&D spending. Adherex notes that…